Biocon arm gets EU GMP certification

On Tuesday, Biocon Ltd informed the bourses that the company’s subsidiary, Biocon Biologics India Ltd has received EU GMP certification for its drug constituent facilities located in Bengaluru.

This good manufacturing practice (GMP) certificate has been received in compliance with EMA, represented by the competent authority of Germany for its biologics drug substance (DS), facilities at Bengaluru.

The above-mentioned facilities are engaged in the manufacturing of drug substance of Pegfilgrastim and Recombinant human insulin. Between January 20 and 23, 2020, these manufacturing-related activities were inspected by the regulatory agency.

With this achievement, the company would further enhance its strength by addressing rising need of the patients in EU markets.

In today’s trading session, the share of Biocon opened at Rs 355.90 and jumped by one per cent and made an intraday high of Rs 356.55 on BSE. The stock had hit 52-week high of Rs 367.80 on April 20, 2020 and 52-week low of Rs 211.30 on August 20, 2019 on BSE.